Analyst consensus rating
Ultragenyx Pharmaceutical Analyst Rating: Buy
Direct answer
Ultragenyx Pharmaceutical's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $26.35.
Forecast evidence checked November 4, 2026.
Get free Ultragenyx Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.63
- Average price target
- $26.35
- High price target
- $39.00
- Low price target
- $16.00
- Low target gap
- -3.8%
- Target upside
- +58.4%
- High target gap
- +134.5%
- Target range width
- 138.3%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a verified Buy consensus. The same dataset has an average price target of $26.35.
How far are Ultragenyx Pharmaceutical's low and high targets from the recorded price?
The low target implies -3.8%, while the high target implies +134.5%.
How many analysts are included in Ultragenyx Pharmaceutical's consensus?
The verified consensus includes 20 analysts.
How is Ultragenyx Pharmaceutical's target upside or downside calculated?
The average target of $26.35 is divided by the recorded price of $16.63, then one is subtracted to produce +58.4%. This does not guarantee a future return.
When was Ultragenyx Pharmaceutical's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.